Renal Cell Carcinoma (RCC)
Home / Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma (RCC)
- Combination Immunotherapy: Dual checkpoint blockade (nivolumab + ipilimumab) provides durable remission in advanced disease.
- VEGF TKIs: Cabozantinib, lenvatinib, and axitinib remain central to controlling angiogenesis.
- Novel Frontline Regimens: Combining TKIs with immunotherapy (e.g., pembrolizumab + axitinib) has improved overall survival in both intermediate- and poor-risk patients.
Your Financial Contribution Can Help Us Fund Critical Programs & Initiatives
As a Nonprofit organization, we are deeply committed to raising awareness, providing patient support, and advocating for research for individuals living with various disease states.
Quick Links
Rare Diseases
Contact Us
For general questions about our organization, our mission, or how you can get involved, please email us. We endeavor to respond to all inquiries